Clearside Biomedical Inc (NASDAQ: CLSD) has experienced a decline in its stock price by -4.30 compared to its previous closing price of 0.93. However, the company has seen a fall of -12.75% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong.
Is It Worth Investing in Clearside Biomedical Inc (NASDAQ: CLSD) Right Now?
The 36-month beta value for CLSD is also noteworthy at 2.20. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLSD is 64.24M, and at present, short sellers hold a 2.08% of that float. The average trading volume of CLSD on December 20, 2024 was 714.16K shares.
CLSD’s Market Performance
The stock of Clearside Biomedical Inc (CLSD) has seen a -12.75% decrease in the past week, with a -15.24% drop in the past month, and a -25.83% fall in the past quarter. The volatility ratio for the week is 6.10%, and the volatility levels for the past 30 days are at 5.35% for CLSD. The simple moving average for the past 20 days is -13.13% for CLSD’s stock, with a -27.00% simple moving average for the past 200 days.
Analysts’ Opinion of CLSD
Many brokerage firms have already submitted their reports for CLSD stocks, with Chardan Capital Markets repeating the rating for CLSD by listing it as a “Buy.” The predicted price for CLSD in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on August 21, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CLSD reach a price target of $5. The rating they have provided for CLSD stocks is “Outperform” according to the report published on June 25th, 2024.
Wedbush gave a rating of “Outperform” to CLSD, setting the target price at $9 in the report published on December 15th of the previous year.
CLSD Trading at -16.64% from the 50-Day Moving Average
After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.02% of loss for the given period.
Volatility was left at 5.35%, however, over the last 30 days, the volatility rate increased by 6.10%, as shares sank -10.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.06% lower at present.
During the last 5 trading sessions, CLSD fell by -10.78%, which changed the moving average for the period of 200-days by -45.51% in comparison to the 20-day moving average, which settled at $1.0255. In addition, Clearside Biomedical Inc saw -23.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLSD starting from Chong Ngai Hang Victor, who purchase 36,500 shares at the price of $1.00 back on Nov 01 ’24. After this action, Chong Ngai Hang Victor now owns 100,000 shares of Clearside Biomedical Inc, valued at $36,500 using the latest closing price.
Chong Ngai Hang Victor, the Chief Medical Officer of Clearside Biomedical Inc, purchase 23,500 shares at $1.06 during a trade that took place back on Jun 24 ’24, which means that Chong Ngai Hang Victor is holding 63,500 shares at $24,910 based on the most recent closing price.
Stock Fundamentals for CLSD
Current profitability levels for the company are sitting at:
- -3.2 for the present operating margin
- 0.99 for the gross margin
The net margin for Clearside Biomedical Inc stands at -4.14. The total capital return value is set at -1.05. Equity return is now at value -1310.02, with -100.27 for asset returns.
Based on Clearside Biomedical Inc (CLSD), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -50.8. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -2.6.
Currently, EBITDA for the company is -23.06 million with net debt to EBITDA at 0.59. When we switch over and look at the enterprise to sales, we see a ratio of 7.2. The receivables turnover for the company is 9.78for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.49.
Conclusion
In summary, Clearside Biomedical Inc (CLSD) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
